Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025 | Manifold

Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025

Plus

21

Ṁ2423

2026

11%

chance

1D

1W

1M

ALL

a black box warning by FDA or withdrawal from market for adverse events by 12/31/2025 resolves this market YES

This question is managed and resolved by Manifold.

#Weight loss drugs

Get

1,000

and

3.00

Sort by:

https://www.biospace.com/article/novo-lilly-weight-loss-drugs-under-fda-scrutiny-for-suicidal-thoughts-hair-loss/

made a related market and added a large subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl?r=QW5keU1hcnRpbg

predictedYES

https://www.nbcnews.com/news/amp/rcna102129

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1656537

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study

Singh et al tested whether glucagonlike peptide 1 (GLP-1)–based therapies such as exenatide and sitagliptin phosphate are associated with an increased risk of a

More reports of gastroparesis https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-drugs-gastroparesis/index.html

They took blockbuster drugs for weight loss and diabetes. Now their stomachs are paralyzed | CNN

Doctors say more cases of people with stomach paralysis after taking popular drugs like Ozempic and Wegovy are coming to light.

Related questions

The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.

Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?

Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?

Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

[ACX 2024] Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?

Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?

Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024

[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?

Related questions

The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.

Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?

Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?

Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024

Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?

[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...

Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

[ACX 2024] Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?

Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?

© Manifold Markets, Inc.•Terms + Mana-only Terms•Privacy•Rules